These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 31440905)

  • 1. Successful Retreatment with Elotuzumab for Multiple Myeloma with Extramedullary Relapse while Being Treated with Lenalidomide and Dexamethasone.
    Oka S; Ono K; Nohgawa M
    Pathol Oncol Res; 2020 Jul; 26(3):1993-1995. PubMed ID: 31440905
    [No Abstract]   [Full Text] [Related]  

  • 2. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial.
    Raab MS; Engelhardt M; Blank A; Goldschmidt H; Agis H; Blau IW; Einsele H; Ferstl B; Schub N; Röllig C; Weisel K; Winderlich M; Griese J; Härtle S; Weirather J; Jarutat T; Peschel C; Chatterjee M
    Lancet Haematol; 2020 May; 7(5):e381-e394. PubMed ID: 32171061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elotuzumab in the treatment of relapsed and refractory multiple myeloma.
    Grosicki S; Bednarczyk M; Barchnicka A; Grosicka O
    Future Oncol; 2021 May; 17(13):1581-1591. PubMed ID: 33478270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment-resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma.
    Iqbal SM; Stecklein K; Sarow J; Krabak M; Hillengass J; McCarthy P
    Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):e33-e36. PubMed ID: 30337238
    [No Abstract]   [Full Text] [Related]  

  • 5. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.
    Richardson PG; Jagannath S; Moreau P; Jakubowiak AJ; Raab MS; Facon T; Vij R; White D; Reece DE; Benboubker L; Zonder J; Tsao LC; Anderson KC; Bleickardt E; Singhal AK; Lonial S;
    Lancet Haematol; 2015 Dec; 2(12):e516-27. PubMed ID: 26686406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
    Schjesvold F; Bringhen S; G Richardson P; Perrot A; Leleu X; Moreau P; A Dimopoulos M; Hulin C; Tekle C; Foster MC; Poole EM; van de Velde H; Facon T
    Am J Hematol; 2021 Nov; 96(11):E423-E427. PubMed ID: 34383345
    [No Abstract]   [Full Text] [Related]  

  • 7. Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high-risk multiple myeloma.
    Biran N; Gourna Paleoudis E; Feinman R; Vesole DH; Zenreich J; Wang S; Ahn J; Bansal M; Rowley S; Donato M; Pecora AL; Richter J; Anand P; McBride L; Ivanovski K; Korngold R; Siegel DS
    Am J Hematol; 2021 Nov; 96(11):E430-E433. PubMed ID: 34435374
    [No Abstract]   [Full Text] [Related]  

  • 8. Elotuzumab in multiple myeloma.
    Bruzzese A; Martino EA; Vigna E; Iaccino E; Mendicino F; Lucia E; Olivito V; Filippelli G; Neri A; Morabito F; Gentile M
    Expert Opin Biol Ther; 2023 Jan; 23(1):7-10. PubMed ID: 36373842
    [No Abstract]   [Full Text] [Related]  

  • 9. Isatuximab for the treatment of relapsed/refractory multiple myeloma.
    Richardson PG; Beksaç M; Špička I; Mikhael J
    Expert Opin Biol Ther; 2020 Dec; 20(12):1395-1404. PubMed ID: 33111607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
    Lonial S; Kaufman J; Reece D; Mateos MV; Laubach J; Richardson P
    Expert Opin Biol Ther; 2016 Oct; 16(10):1291-301. PubMed ID: 27533882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial.
    Dimopoulos MA; Lonial S; Betts KA; Chen C; Zichlin ML; Brun A; Signorovitch JE; Makenbaeva D; Mekan S; Sy O; Weisel K; Richardson PG
    Cancer; 2018 Oct; 124(20):4032-4043. PubMed ID: 30204239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial.
    Leypoldt LB; Besemer B; Asemissen AM; Hänel M; Blau IW; Görner M; Ko YD; Reinhardt HC; Staib P; Mann C; Lutz R; Munder M; Graeven U; Peceny R; Salwender H; Jauch A; Zago M; Benner A; Tichy D; Bokemeyer C; Goldschmidt H; Weisel KC
    Leukemia; 2022 Mar; 36(3):885-888. PubMed ID: 34732857
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study.
    Berdeja J; Jagannath S; Zonder J; Badros A; Kaufman JL; Manges R; Gupta M; Tendolkar A; Lynch M; Bleickardt E; Paliwal P; Vij R
    Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):129-38. PubMed ID: 26795075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites.
    Chehab S; Zhang C; Panjic EH; Chen Z; Kaufman JL; Lonial S; Nooka A; Harvey RD
    Cancer; 2018 Nov; 124(22):4358-4365. PubMed ID: 30303526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elotuzumab: no benefit for older patients with newly diagnosed multiple myeloma.
    Touzeau C
    Lancet Haematol; 2022 Jun; 9(6):e386-e387. PubMed ID: 35550059
    [No Abstract]   [Full Text] [Related]  

  • 16. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
    Lonial S; Dimopoulos M; Palumbo A; White D; Grosicki S; Spicka I; Walter-Croneck A; Moreau P; Mateos MV; Magen H; Belch A; Reece D; Beksac M; Spencer A; Oakervee H; Orlowski RZ; Taniwaki M; Röllig C; Einsele H; Wu KL; Singhal A; San-Miguel J; Matsumoto M; Katz J; Bleickardt E; Poulart V; Anderson KC; Richardson P;
    N Engl J Med; 2015 Aug; 373(7):621-31. PubMed ID: 26035255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
    Campbell KS; Cohen AD; Pazina T
    Front Immunol; 2018; 9():2551. PubMed ID: 30455698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Successful treatment with a combination of elotuzumab, lenalidomide and dexamethasone of extramedullary disease in a patient with refractory multiple myeloma].
    Kashima E; Fujieda A; Nato Y; Ino K; Tawara I; Masuya M; Katayama N
    Rinsho Ketsueki; 2020; 61(3):223-227. PubMed ID: 32224581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.
    Richardson PG; Facon T; Bensinger WI; Leleu X; Campana F; Macé S; Chiron M; van de Velde H; Mikhael J
    Blood Cancer J; 2021 Mar; 11(3):55. PubMed ID: 33712562
    [No Abstract]   [Full Text] [Related]  

  • 20. Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma.
    Lamb YN
    Drugs; 2018 Sep; 78(14):1481-1488. PubMed ID: 30232695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.